Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Vicarious Surgical’s SEC paperwork often means decoding pages of robotics engineering details, FDA trial data, and prototype cost breakdowns. If you have ever searched for “Vicarious Surgical SEC filings explained simply” or wondered how executive stock sales line up with regulatory milestones, you know the challenge.
Stock Titan solves that complexity. Our AI instantly scans every new document from the company’s real-time EDGAR feed—whether it’s a Vicarious Surgical quarterly earnings report 10-Q filing or a sudden Vicarious Surgical 8-K material events explained alert—and delivers plain-language summaries, trend charts, and red-flag highlights. You will see cash-burn trends, R&D outlays, and single-port robotics development updates without wading through technical jargon.
Here is what investors monitor most—and how our platform helps:
- 10-K / Annual insight: Get the Vicarious Surgical annual report 10-K simplified so you can track FDA pathway progress and component sourcing risks.
- 10-Q / Quarterly performance: Compare revenue runway and prototype expenses with our Vicarious Surgical earnings report filing analysis.
- Form 4 insider alerts: Follow Vicarious Surgical insider trading Form 4 transactions and receive Vicarious Surgical Form 4 insider transactions real-time push notices.
- Proxy statement: Drill into Vicarious Surgical proxy statement executive compensation to see how bonuses hinge on FDA milestones.
Need deeper context? Try understanding Vicarious Surgical SEC documents with AI—our narrative commentary ties robotic-arm dexterity claims to actual spending, while clear call-outs show Vicarious Surgical executive stock transactions Form 4 right next to board meeting dates. From early-morning 8-K announcements to late-day amendment filings, every disclosure appears on this page within minutes, already distilled into the insights that matter.
Khalifa Sammy, listed as Chief Technology Officer, director and a 10% owner of Vicarious Surgical Inc. (RBOT), reported a non-discretionary sale on 08/20/2025 of 653 shares of Class A common stock to satisfy tax withholding obligations arising from restricted stock units granted on May 19, 2022. The weighted average sale price was $6.0422, with individual trades ranging from $5.90 to $6.32. After the transaction, the reporting person beneficially owned 34,754 shares directly. The Form 4 was filed by one reporting person and signed on 08/21/2025 by an attorney-in-fact.
Adam David Sachs, President and Director of Vicarious Surgical Inc. (RBOT), sold 817 shares of Class A common stock on 08/20/2025 to satisfy tax withholding on vested restricted stock units. The sales were executed as a mandatory "sell to cover" under the company's equity plan and are not discretionary trades. The weighted average sale price was $6.0312 per share, with individual trade prices ranging from $5.90 to $6.32. After the transaction Sachs beneficially owned 49,627 shares. The Form 4 was signed by an attorney-in-fact on 08/21/2025.
Director Donald F. Tang reported open-market dispositions of Vicarious Surgical Inc. (RBOT) common stock. He sold 100 shares on 08/19/2025 at $6.68 and 2,059 shares on 08/20/2025 at $6.04, reducing his direct holdings from 45,237 shares to 43,178 shares. The form is signed by an attorney-in-fact and does not disclose any derivative transactions or additional context.
Form 144 notice for Vicarious Surgical Inc. (RBOT) reports a proposed sale of Class A common stock through UBS Financial Services. The filing shows 817 shares proposed for sale with an aggregate market value of $5,212.46 and lists the approximate sale date as 08/20/2025 on the NYSE. The securities were acquired by the reporting person on 08/19/2025 as a restricted stock lapse, with 2,378 shares noted as acquired on that date. The filing also discloses three sales by the same seller in the past three months: 817 shares on 05/20/2025 for $5,961, 463 shares on 06/03/2025 for $3,210, and 279 shares on 06/23/2025 for $2,067. The notice includes the seller’s signed representation that they are not aware of any undisclosed material adverse information about the issuer.
Vicarious Surgical Inc. (RBOT) filing is a Form 144 notice reporting proposed sales of Class A common stock by an insider. The filing lists a planned sale of 653 shares through UBS Financial Services with an aggregate market value of $4,166.14 and an approximate sale date of 08/20/2025 on the NYSE. The securities were acquired on 08/19/2025 by restricted stock lapse, showing 1,902 shares acquired in that transaction. The filer also disclosed three prior sales in the past three months totaling 1,115 shares with gross proceeds of $8,039 on 05/20/2025, 06/03/2025, and 06/23/2025. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Vicarious Surgical Inc. remains pre-revenue and reported a six-month net loss of $28.6 million and a three-month net loss of $13.2 million. Total assets declined to $40.9 million from $67.7 million, driven by lower cash and short-term investments. Cash and cash equivalents were $3.9 million and short-term investments were $20.1 million, totaling $23.96 million at June 30, 2025.
Management disclosed that these funds are insufficient to support operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern and requiring pursuit of additional equity or debt financing. The company reduced operating expenses year-over-year (R&D, G&A and S&M), improving loss from operations by ~13% for the six-month comparison. The NYSE notified the company of non-compliance with market capitalization standards but accepted the company’s cure plan for the specified review period. A CEO appointment was announced as a subsequent event.
Vicarious Surgical Inc. furnished a Current Report announcing that it issued a press release with its results for the second quarter ended June 30, 2025 and providing a business update. The 8-K attaches that press release as Exhibit 99.1 and includes an Inline XBRL cover page file as Exhibit 104. The filing states the furnished materials are not "filed" for purposes of the Exchange Act and are not incorporated by reference elsewhere unless explicitly stated. The report does not include financial tables, numerical earnings or balance sheet figures within the filing itself; readers must consult the attached press release for detailed results.
Vicarious Surgical director Ahmad Fuad acquired a stock option on June 27, 2025 giving the right to purchase 8,003 Class A common shares at an exercise price of $7.61. The option is reported as directly beneficially owned and has an expiration date of June 26, 2035.
The filing states the shares underlying the option will vest on June 27, 2026 (or one day prior to the issuer's next annual meeting), subject to continued service. The Form 4 was executed by an attorney-in-fact on August 11, 2025. The disclosure shows a routine director option grant with defined exercise price, vesting schedule, and expiration; no sales or dispositions are reported here.
Khalifa Sammy, identified as a director, a 10% owner and Chief Technology Officer of Vicarious Surgical Inc. (RBOT), reported an equity award on 06/27/2025. The filing shows acquisition of 25,025 stock options with an exercise price of $7.61. The options vest in 48 equal monthly installments beginning on the one-month anniversary of the grant, tying vesting to continued service. The options appear to carry a term that ends on 06/26/2035, and the number of derivative securities beneficially owned following the transaction is 25,025. The form is signed by an attorney-in-fact on 08/11/2025.
Donald F. Tang, a director of Vicarious Surgical Inc. (ticker: RBOT), reported receipt of a stock option on 06/27/2025. The option covers 5,335 underlying shares of Class A common stock with an exercise price of $7.61. The filing states all shares underlying the option will vest on June 27, 2026 or one day prior to the issuer's next annual meeting, whichever is earlier, provided the reporting person remains in service through the vesting date. The Form 4 shows the report was signed by an attorney-in-fact, Erin Checka, on 08/11/2025.
FAQ
What is the current stock price of Vicarious Surgical (RBOT)?
What is the market cap of Vicarious Surgical (RBOT)?
